EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions

Charlotte S Walmsley, Adela Rodriguez, Panagiotis A Konstantinopoulos, Geoffrey I Shapiro, Sara M Tolaney, Judy E Garber, Filipa Lynce

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207632 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Charlotte S Walmsley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Recombinational DNA Repair. Die Arbeit nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination repair deficiency (HRD) occurs in approximately 10% of breast tumors and represents a major targetable vulnerability across multiple cancer types. Impairment of the homologous recombination DNA repair pathway — arising through somatic and germline mutations in homologous recombination repair genes, epigenetic mechanisms, and transcriptomic changes — leads to genomic instability and a reliance on error-prone repair mechanisms. Poly (ADP-ribose) polymerase (PARP) inhibitors harness the synthetic lethality of HRD and PARP inhibition, with current approvals encompassing both early-stage and advanced breast cancer in patients with germline BRCA1/2 (g BRCA1/2 ) mutations. However, emerging evidence suggests efficacy of PARP inhibitors beyond g BRCA1/2 -mutated breast cancer to tumors with other homologous recombination repair defects that confer a “BRCAness” phenotype. This Review examines opportunities to broaden the use of PARP inhibitors in breast cancer and underscores the importance of innovative biomarkers, combination strategies, and next-generation agents to maximize therapeutic impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairHumansFemaleBRCA1 ProteinBRCA2 ProteinGerm-Line MutationAnimalsPoly(ADP-ribose) Polymerases

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA2 ProteinBRCA2 protein, humanBRCA1 protein, humanPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Zitieren

APA

Walmsley, C. S., Rodriguez, A., Konstantinopoulos, P. A., Shapiro, G. I., Tolaney, S. M., Garber, J. E., & Lynce, F. (2026). Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions. Journal of Clinical Investigation. https://doi.org/10.1172/jci207632

Vancouver

Walmsley CS, Rodriguez A, Konstantinopoulos PA, Shapiro GI, Tolaney SM, Garber JE, et al. Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions. Journal of Clinical Investigation. 2026. doi:10.1172/jci207632

BibTeX
@article{Walmsley2026,
  author = {Walmsley, Charlotte S and Rodriguez, Adela and Konstantinopoulos, Panagiotis A and Shapiro, Geoffrey I and Tolaney, Sara M and Garber, Judy E and Lynce, Filipa},
  title = {Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207632}
}
Kostenlos starten →